West Pharmaceutical Services/$WST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About West Pharmaceutical Services
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Ticker
$WST
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
10,600
ISIN
US9553061055
Website
WST Metrics
BasicAdvanced
$16B
34.34
$6.37
1.22
$0.83
0.38%
Price and volume
Market cap
$16B
Beta
1.22
52-week high
$348.90
52-week low
$187.43
Average daily volume
645K
Dividend rate
$0.83
Financial strength
Current ratio
2.767
Quick ratio
1.848
Long term debt to equity
10.603
Total debt to equity
11.457
Dividend payout ratio (TTM)
12.76%
Interest coverage (TTM)
331.50%
Profitability
EBITDA (TTM)
756.5
Gross margin (TTM)
34.54%
Net profit margin (TTM)
16.13%
Operating margin (TTM)
20.70%
Effective tax rate (TTM)
19.78%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
10.38%
Return on equity (TTM)
17.42%
Valuation
Price to earnings (TTM)
34.339
Price to revenue (TTM)
5.499
Price to book
5.86
Price to tangible book (TTM)
6.13
Price to free cash flow (TTM)
51.883
Free cash flow yield (TTM)
1.93%
Free cash flow per share (TTM)
421.86%
Dividend yield (TTM)
0.38%
Forward dividend yield
0.38%
Growth
Revenue change (TTM)
-1.12%
Earnings per share change (TTM)
-15.97%
3-year revenue growth (CAGR)
0.17%
10-year revenue growth (CAGR)
7.46%
3-year earnings per share growth (CAGR)
-10.76%
10-year earnings per share growth (CAGR)
13.36%
3-year dividend per share growth (CAGR)
5.42%
10-year dividend per share growth (CAGR)
6.92%
What the Analysts think about WST
Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.
Bulls say / Bears say
West Pharmaceutical Services raised its annual profit and sales forecasts for 2025, citing benefits from a weaker U.S. dollar and anticipated strong demand for medical devices. (reuters.com)
The company reported Q1 2025 adjusted earnings per share of $1.45, surpassing analyst expectations of $1.23, indicating strong financial performance. (benzinga.com)
Analysts at Evercore ISI Group initiated coverage on West Pharmaceutical Services with an 'Outperform' rating and a price target of $275, reflecting confidence in the company's growth prospects. (benzinga.com)
West Pharmaceutical Services projected adjusted EPS of $6.00-$6.20 for full-year 2025, significantly below the consensus estimate of $7.44, leading to a stock price decline of over 38% following the earnings release. (monexa.ai)
The company anticipates a $20 to $25 million impact from recently implemented tariffs for the remainder of 2025, which could affect profitability. (benzinga.com)
West Pharmaceutical Services' operating margin declined to 15.3% in Q1 2025 from 17.7% in the same quarter last year, indicating potential challenges in maintaining profitability. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
WST Financial Performance
Revenues and expenses
WST Earnings Performance
Company profitability
WST News
AllArticlesVideos
Levi & Korsinsky Notifies West Pharmaceutical Services, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – WST
GlobeNewsWire·1 hour ago
Deadline Alert: West Pharmaceutical Services, Inc. (WST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
GlobeNewsWire·4 hours ago
WST FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 7 Deadline in Securities Class Action – WST
GlobeNewsWire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul30
West Pharmaceutical Services
Dividend·Ex-dividend
Aug6
West Pharmaceutical Services
Dividend·Payment
$0.21Per share
FAQs
What’s the current market cap for West Pharmaceutical Services stock?
West Pharmaceutical Services (WST) has a market cap of $16B as of June 30, 2025.
What is the P/E ratio for West Pharmaceutical Services stock?
The price to earnings (P/E) ratio for West Pharmaceutical Services (WST) stock is 34.34 as of June 30, 2025.
Does West Pharmaceutical Services stock pay dividends?
Yes, the West Pharmaceutical Services (WST) stock pays dividends to shareholders. As of June 30, 2025, the dividend rate is $0.83 and the yield is 0.38%. West Pharmaceutical Services has a payout ratio of 12.76% on a trailing twelve-month basis.
When is the next West Pharmaceutical Services dividend payment date?
The next West Pharmaceutical Services (WST) dividend payment is scheduled for August 06, 2025.
What is the beta indicator for West Pharmaceutical Services?
West Pharmaceutical Services (WST) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.